Welcome to our dedicated page for Xtant Medical SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading an FDA-focused 10-K packed with clinical data or hunting down surgeon adoption metrics in an 8-K can feel overwhelming. Xtant Medical鈥檚 filings layer medical terminology atop SEC language, making it hard to spot what really moves revenue鈥攏ew orthobiologic launches, device recalls, or shifts in donor-tissue supply.
Stock Titan鈥檚 AI-powered summaries untangle that complexity. Whether you need the Xtant Medical quarterly earnings report 10-Q filing or the latest Xtant Medical insider trading Form 4 transactions, our platform explains each section in clear English, flags FDA risk statements, and highlights cash-flow drivers鈥攂efore you read a single footnote. AG真人官方-time alerts ensure Xtant Medical Form 4 insider transactions arrive the moment executives trade.
All filing types are here: the Xtant Medical annual report 10-K simplified for long-term strategy, 8-K material events explained for sudden developments like product launches, and the proxy statement covering Xtant Medical executive compensation. Need quick context? Ask natural questions like 鈥渦nderstanding Xtant Medical SEC documents with AI鈥� or 鈥淴tant Medical earnings report filing analysis鈥� and receive instant, reference-linked answers.
From tracking Xtant Medical executive stock transactions Form 4 to comparing biologic versus implant revenue across quarters, professionals save hours while making well-informed decisions. Complex filings made clear, updated the moment EDGAR publishes.
Xtant Medical Holdings, Inc. established November 7, 2025 as the date for its 2025 Annual Meeting of Stockholders and said it anticipates printing the proxy statement on or about September 12, 2025 and mailing or making it available commencing on or about September 15, 2025. The company noted the meeting date changed by more than 30 days from last year.
Because of that change, stockholder proposals under Rule 14a-8 must be received at the company鈥檚 principal executive offices by the close of business on August 18, 2025. Other stockholder proposals and director nominations under the Bylaws also must be delivered in writing to the Corporate Secretary by August 18, 2025. Stockholders seeking to solicit proxies for alternative director nominees must comply with the universal proxy requirements, including providing written notice no later than September 8, 2025.
FAQ
What is the current stock price of Xtant Medical (XTNT)?
What is the market cap of Xtant Medical (XTNT)?
